Drug Research
canSERV, EU Cluster Effort, Offers Cancer Study In Europe
Brussels marks the beginning of the European canSERV initiative, which aims to defragment the European cancer research landscape. CanSERV will give academia and business exposure to cross-cutting services and assistance from fundamental science up to clinical application over the...
Drug Research
WHO Strongly Advises Against The Use of 2 COVID Therapies
The World Health Organization (WHO) has discontinued the use of two COVID-19 antibody treatments on the grounds that Omicron and the variant's most recent offspring have probably made them ineffective.
The two treatments were among the first drugs created in...
Drug Research
Despite Rising Illness, Cambodian Pharma Sees Less Potential
Despite the increased prevalence of both communicable and non-communicable diseases in the nation, the commercial potential for medication manufacturers in Cambodia will remain restricted, according to a report by Fitch Solutions.
Based on the report, Cambodia's healthcare system is still...
Drug Research
Hemophilia Gene Cures From BioMarin, CSL Win ICER Support
Upcoming gene therapies may be the most economical option for people with haemophilia types A and B to address their illness, even with a steep price tag of $2.5 million for each treatment. In a preliminary evidence report made...
Drug Research
WHO Demands More Study On People Living With Long COVID
The WHO has urged nations to invest promptly in research, recovery, and rehabilitation in order to treat the post-COVID-19 syndrome seriously.
At least 17 million people in the 53 Member States of the WHO European Region may have encountered post-COVID-19...
Drug Research
$300mn Pledged By Novartis For European Biotherapeutics
The next-generation biotherapeutics will receive $300 million from Novartis, according to the company. To build a fully integrated, dedicated scientific environment to boost its capabilities and capacity for early technological development of biologics, the multi-year investment will be deployed...
Drug Research
Prior To FDA Prurigo Nodularis Ruling, Dupixent Wins Again
Dupixent, the immunology favourite developed by Sanofi and Regeneron Pharmaceuticals, is still on the rise. It has received back-to-back approvals this year for the treatment of eosinophilic esophagitis and paediatric eczema, and now the IL-4/IL-13 inhibitor has achieved a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read